.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Novartis
Julphar
US Department of Justice
Teva
Baxter
Chinese Patent Office
Express Scripts
Fish and Richardson
Moodys

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: RE44186

« Back to Dashboard

Which drugs does patent RE44186 protect, and when does it expire?


Patent RE44186 protects KOMBIGLYZE XR, ONGLYZA, and QTERN, and is included in three NDAs. There have been zero Paragraph IV challenges on Onglyza and Kombiglyze XR

This patent has sixty-seven patent family members in thirty-two countries.

Summary for Patent: RE44186

Title:Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula ##STR00001## where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
Inventor(s): Robl; Jeffrey A. (Newtown, PA), Sulsky; Richard B. (Pennington, NJ), Augeri; David J. (Princeton, NJ), Magnin; David R. (Sumter, SC), Hamann; Lawrence G. (Cambridge, MA), Betebenner; David A. (Lawrenceville, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:13/308,658
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca AbKOMBIGLYZE XRmetformin hydrochloride; saxagliptin hydrochlorideTABLET, EXTENDED RELEASE;ORAL200678-003Nov 5, 2010RXYesNo► Subscribe► SubscribeYYMETHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN► Subscribe
Astrazeneca AbKOMBIGLYZE XRmetformin hydrochloride; saxagliptin hydrochlorideTABLET, EXTENDED RELEASE;ORAL200678-003Nov 5, 2010RXYesNo► Subscribe► SubscribeYYADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENTWITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE► Subscribe
Astrazeneca AbKOMBIGLYZE XRmetformin hydrochloride; saxagliptin hydrochlorideTABLET, EXTENDED RELEASE;ORAL200678-002Nov 5, 2010RXYesYes► Subscribe► SubscribeYYMETHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN► Subscribe
Astrazeneca AbKOMBIGLYZE XRmetformin hydrochloride; saxagliptin hydrochlorideTABLET, EXTENDED RELEASE;ORAL200678-002Nov 5, 2010RXYesYes► Subscribe► SubscribeYYADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENTWITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE► Subscribe
Astrazeneca AbKOMBIGLYZE XRmetformin hydrochloride; saxagliptin hydrochlorideTABLET, EXTENDED RELEASE;ORAL200678-001Nov 5, 2010RXYesNo► Subscribe► SubscribeYYADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENTWITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE► Subscribe
Astrazeneca AbKOMBIGLYZE XRmetformin hydrochloride; saxagliptin hydrochlorideTABLET, EXTENDED RELEASE;ORAL200678-001Nov 5, 2010RXYesNo► Subscribe► SubscribeYYMETHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN► Subscribe
Astrazeneca AbONGLYZAsaxagliptin hydrochlorideTABLET;ORAL022350-001Jul 31, 2009RXYesNo► Subscribe► SubscribeYYMETHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN► Subscribe
Astrazeneca AbONGLYZAsaxagliptin hydrochlorideTABLET;ORAL022350-001Jul 31, 2009RXYesNo► Subscribe► SubscribeYYMETHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA► Subscribe
Astrazeneca AbONGLYZAsaxagliptin hydrochlorideTABLET;ORAL022350-002Jul 31, 2009RXYesYes► Subscribe► SubscribeYYMETHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN► Subscribe
Astrazeneca AbONGLYZAsaxagliptin hydrochlorideTABLET;ORAL022350-002Jul 31, 2009RXYesYes► Subscribe► SubscribeYYMETHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: RE44186

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,395,767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE44186

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina027634► Subscribe
Austria396176► Subscribe
Australia2001245466► Subscribe
Australia4546601► Subscribe
Brazil0109115► Subscribe
Canada2402894► Subscribe
China1213028► Subscribe
China1427826► Subscribe
China1698601► Subscribe
Colombia5280198► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Merck
Cantor Fitzgerald
AstraZeneca
US Army
Deloitte
Citi
Julphar
Johnson and Johnson
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot